1. Home
  2. NRDS vs ZVRA Comparison

NRDS vs ZVRA Comparison

Compare NRDS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

HOLD

Current Price

$9.58

Market Cap

720.4M

Sector

Technology

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$14.48

Market Cap

741.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRDS
ZVRA
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
720.4M
741.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
NRDS
ZVRA
Price
$9.58
$14.48
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$15.00
$23.00
AVG Volume (30 Days)
722.0K
1.8M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
68.42
159.21
EPS
0.29
0.60
Revenue
$836,600,000.00
$106,470,000.00
Revenue This Year
$10.13
$37.27
Revenue Next Year
$7.11
$53.42
P/E Ratio
$32.69
$23.28
Revenue Growth
21.67
350.91
52 Week Low
$7.33
$7.16
52 Week High
$16.24
$14.58

Technical Indicators

Market Signals
Indicator
NRDS
ZVRA
Relative Strength Index (RSI) 65.82 68.07
Support Level $9.26 $8.26
Resistance Level $10.83 N/A
Average True Range (ATR) 0.32 0.59
MACD 0.15 0.05
Stochastic Oscillator 85.85 93.13

Price Performance

Historical Comparison
NRDS
ZVRA

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: